Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encysive TBC3711 On Clinical Hold

This article was originally published in The Pink Sheet Daily

Executive Summary

Encysive's next-generation selective endothelin receptor antagonist TBC3711 is subject to a clinical hold following an unexpected result in pre-clinical work
Advertisement

Related Content

Encysive Hits Another Snag With Thelin
Encysive Hits Another Snag With Thelin
Encysive Avoids Additional Trials For Thelin NDA
Encysive Avoids Additional Trials For Thelin NDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS063902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel